Exploring the complex relationship between metabolomics and breast cancer early detection (Review)

Alshajrawi,Omar Mahmoud; Tengku Din,Tengku Ahmad Damitri Al Astani Tengku Din; Marzuki,Shahira Sofea Binti; Maulidiani,Maulidiani; Mohd Rusli,Nurul Anaqi Rukaini Binti; Badrol Hisham,Norul Faezzatul Ain Binti; Hui Ying,Lim; Yahya,Maya Mazuwin Binti; Wan Azman,Wan Norlina Binti; Ramli,Ras A.; Wan Abdul Rahman,Wan Faiziah

doi:10.3892/mco.2025.2830

Exploring the complex relationship between metabolomics and breast cancer early detection (Review)

Authors:
- Omar Mahmoud Alshajrawi
- Tengku Ahmad Damitri Al Astani Tengku Din Tengku Din
- Shahira Sofea Binti Marzuki
- Maulidiani Maulidiani
- Nurul Anaqi Rukaini Binti Mohd Rusli
- Norul Faezzatul Ain Binti Badrol Hisham
- Lim Hui Ying
- Maya Mazuwin Binti Yahya
- Wan Norlina Binti Wan Azman
- Ras A. Ramli
- Wan Faiziah Wan Abdul Rahman
View Affiliations

Affiliations: Department of Chemical Pathology, School of Medical Science, Health Campus, University Sains Malaysia, Kubang Kerian, Kelantan 16150, Malaysia, Faculty of Science and Marine Environment, University Malaysia Terengganu, Kuala Nerus, Terengganu 21030, Malaysia, Department of Surgery, School of Medical Science, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan 16150, Malaysia, Faculty of Medicine, University Sultan Zainal Abidin, Kuala Terengganu, Terengganu 20400, Malaysia, Department of Pathology, School of Medical Science, Health Campus, University Sains Malaysia, Kubang Kerian, Kelantan 16150, Malaysia
Published online on: February 20, 2025 https://doi.org/10.3892/mco.2025.2830
Article Number: 35
Copyright: © Alshajrawi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An overview of metabolomics in cancer research, focusing on the identification of biomarkers, pharmacological targets and therapeutic agents, is provided in the present review. The fundamentals of metabolomics, the role of metabolites in cancer emergence and the methods used in metabolomic analysis, are reviewed. The applications of metabolomics in cancer therapy and diagnostics, as well as the challenges encountered in metabolomic research, are discussed. Finally, the potential clinical uses of metabolomics in cancer research and its future possibilities are explored, emphasising the importance of non‑invasive diagnostic and monitoring techniques. The present review highlights the significance of metabolite‑based metabolomics as a specialised tool for illuminating disease processes and identifying treatment potentials. The malfunctioning of metabolomic pathways and metabolite accumulation or depletion is caused by metabolomics abnormalities. Metabolite signatures close to a subject's phenotypic informative dimension can be used to monitor therapies and disease prediction diagnosis and prognosis. Non‑invasive diagnostic and monitoring techniques with high specificity and selectivity are urgently needed. Metabolite‑based metabolomics is a specialised metabolic biomarker and pathway‑analysis technique, illuminating the putative processes of numerous human illnesses and determining treatment potentials. Locating biochemical pathway modifications that are early warning signs of pathological malfunction and illness is possible by identifying functional biomarkers linked to phenotypic variance. Scientists generated numerous metabolomics profiles to disclose the underlying processes and metabolomics networks for therapeutic target research in biomedicine. The metabolomic analysis of the potential utility of metabolites as biomarkers for clinical events is summarised in the present review. The significance of metabolite‑based metabolomics as a specialised tool for illuminating disease processes and identifying treatment potentials is highlighted.

View Figures

View References

1	Jobard E, Dossus L, Baglietto L, Fornili M, Lécuyer L, Mancini FR, Gunter MJ, Trédan O, Boutron-Ruault MC, Elena-Herrmann B, et al: Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: A case-control study nested within the French E3N cohort. Br J Cancer. 124:1734–1743. 2021.PubMed/NCBI View Article : Google Scholar
2	Wang Q and Xu R: MetabolitePredict: A de novo human metabolomics prediction system and its applications in rheumatoid arthritis. J Biomed Inform. 71:222–228. 2017.PubMed/NCBI View Article : Google Scholar
3	Silva CL, Olival A, Perestrelo R, Silva P, Tomás H and Câmara JS: Untargeted urinary¹H NMR-based metabolomic pattern as a potential platform in breast cancer detection. Metabolites. 9(269)2019.PubMed/NCBI View Article : Google Scholar
4	Morad HM, Abou-Elzahab MM, Aref S and El-Sokkary AMA: Diagnostic value of ¹H NMR-based metabolomics in acute lymphoblastic leukemia, acute myeloid leukemia, and breast cancer. ACS Omega. 7:8128–8140. 2022.PubMed/NCBI View Article : Google Scholar
5	Patel A: Benign vs malignant tumors. JAMA Oncol. 6(1488)2020.PubMed/NCBI View Article : Google Scholar
6	Britt KL, Cuzick J and Phillips KA: Key steps for effective breast cancer prevention. Nat Rev Cancer. 20:417–436. 2020.PubMed/NCBI View Article : Google Scholar
7	Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the year 2020: An overview. Int J Cancer. 149:778–789. 2021.PubMed/NCBI View Article : Google Scholar
8	Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV and Mitsis M: Breast cancer in young women: An overview. Updates Surg. 69:313–317. 2017.PubMed/NCBI View Article : Google Scholar
9	Nicolini A, Ferrari P and Duffy MJ: Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 52:56–73. 2018.PubMed/NCBI View Article : Google Scholar
10	Li J, Guan X, Fan Z, Ching LM, Li Y, Wang X, Cao WM and Liu DX: Non-invasive biomarkers for early detection of breast cancer. Cancers (Basel). 12(2767)2020.PubMed/NCBI View Article : Google Scholar
11	Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and Farahmand L: Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 84(106535)2020.PubMed/NCBI View Article : Google Scholar
12	Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and Farahmand L: Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 84(106535)2020.PubMed/NCBI View Article : Google Scholar
13	Waks AG and Winer EP: Breast cancer treatment: A review. JAMA. 321:288–300. 2019.PubMed/NCBI View Article : Google Scholar
14	Sharma GN, Dave R, Sanadya J, Sharma P and Sharma KK: Various types and management of breast cancer: An overview. J Adv Pharm Technol Res. 1:109–126. 2010.PubMed/NCBI
15	Akram M, Iqbal M, Daniyal M and Khan AU: Awareness and current knowledge of breast cancer. Biol Res. 50(33)2017.PubMed/NCBI View Article : Google Scholar
16	Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 5:77–106. 2018.PubMed/NCBI View Article : Google Scholar
17	Thirumurugan D, Cholarajan A, Raja SSS and Vijayakumar R: An introductory chapter: Secondary metabolites. In: Vijayakumar R, Raja SSS (edis). Secondary Metabolites-Sources and Applications. Crotia: InTech-Open Science, pp138, 2018.
18	Chen H and Wang L: Sugar strategies for biomass biochemical conversion. Technologies for Biochemical Conversion of Biomass. Metallurgical Industry Press, pp137-164, 2017.
19	Abdel-Aziz SM, Abo Elsoud MM and Anise AAH: Microbial biosynthesis: A repertory of vital natural products. Food Biosynthesis. Elsevier Inc., 25-54, 2017.
20	Tiwari R and Rana CS: Plant secondary metabolites: A review. Int J Eng Res Gen Sci. 3:661–670. 2015.
21	Chandran H, Meena M, Barupal T and Sharma K: Plant tissue culture as a perpetual source for production of industrially important bioactive compounds. Biotechnol Rep (Amst). 26(e00450)2020.PubMed/NCBI View Article : Google Scholar
22	Abdullah MA, Bahamid AAA, Alshajrawi OMS, Nazir MS and Tahir Z: Integrated biomaterials engineering of oil palm fibres and microalgae for bioenergy, environmental remediation, and conversion into value-added-products. IOP Conf Ser Earth Environ Sci. 448(012091)2020.
23	Jones DP, Park Y and Ziegler TR: Nutritional metabolomics: Progress in addressing complexity in diet and health. Annu Rev Nutr. 32:183–202. 2012.PubMed/NCBI View Article : Google Scholar
24	Hanna VS and Hafez EAA: Synopsis of arachidonic acid metabolism: A review. J Adv Res. 11:23–32. 2018.PubMed/NCBI View Article : Google Scholar
25	Pezzuto F, Buonaguro L, Buonaguro FM and Tornesello ML: The role of circulating free DNA and MicroRNA in non-invasive diagnosis of HBV- and HCV-related hepatocellular carcinoma. Int J Mol Sci. 19(1007)2018.PubMed/NCBI View Article : Google Scholar
26	Lu T and Li J: Clinical applications of urinary cell-free DNA in cancer: Current insights and promising future. Am J Cancer Res. 7:2318–2332. 2017.PubMed/NCBI
27	Nam H, Chung BC, Kim Y, Lee KY and Lee D: Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics. 25:3151–3157. 2009.PubMed/NCBI View Article : Google Scholar
28	Henneges C, Bullinger D, Fux R, Friese N, Seeger H, Neubauer H, Laufer S, Gleiter CH, Schwab M, Zell A and Kammerer B: Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection. BMC Cancer. 9(104)2009.PubMed/NCBI View Article : Google Scholar
29	Dinges SS, Hohm A, Vandergrift LA, Nowak J, Habbel P, Kaltashov IA and Cheng LL: Cancer metabolomic markers in urine: Evidence, techniques and recommendations. Nat Rev Urol. 16:339–362. 2019.PubMed/NCBI View Article : Google Scholar
30	Frickenschmidt A, Frohlich H, Bullinger D, Zell A, Laufer S, Gleiter CH, Liebich H and Kammerer B: Metabonomics in cancer diagnosis: Mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers. 13:435–449. 2008.PubMed/NCBI View Article : Google Scholar
31	Chen Y, Zhang R, Song Y, He J, Sun J, Bai J, An Z, Dong L, Zhan Q and Abliz Z: RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: Finding potential biomarkers for breast cancer. Analyst. 134:2003–2011. 2009.PubMed/NCBI View Article : Google Scholar
32	Cho SH, Jung BH, Lee SH, Lee WY, Kong G and Chung BC: Direct determination of nucleosides in the urine of patients with breast cancer using column-switching liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 20:1229–1236. 2006.PubMed/NCBI View Article : Google Scholar
33	Lécuyer L, Victor Bala A, Deschasaux M, Bouchemal N, Nawfal Triba M, Vasson MP, Rossary A, Demidem A, Galan P, Hercberg S, et al: NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer. Int J Epidemiol. 47:484–494. 2018.PubMed/NCBI View Article : Google Scholar
34	Lecuyer L, Dalle C, Lyan B, Demidem A, Rossary A, Vasson MP, Petera M, Lagree M, Ferreira T, Centeno D, et al: Plasma metabolomic signatures associated with long-term breast cancer risk in the SU.VI.MAX prospective cohort. Cancer Epidemiol Biomarkers Prev. 28:1300–1307. 2019.PubMed/NCBI View Article : Google Scholar
35	An R, Yu H, Wang Y, Lu J, Gao Y, Xie X and Zhang J: Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer. Cancer Metab. 10(13)2022.PubMed/NCBI View Article : Google Scholar
36	Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E and Benedetti Panici P: Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer. Tumour Biol. 39(1010428317695525)2017.PubMed/NCBI View Article : Google Scholar
37	Ilyas MN, Ab A, Al-Hatamleh MAI, Al-Shajrawi OM, Ariff TM and Simbak N: Rising trends of obesity in Malaysia; role of inflammation and inflammatory markers in obesity related insulin resistance: A nuclear factor kappa B (Nfkb) perspective. Exp Clin Endocrinol Diabetes. 109:S135–S148. 2017.
38	Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, Smolarczyk R and Meczekalski B: Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 22(3789)2021.PubMed/NCBI View Article : Google Scholar
39	Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W and Sawyer MB: Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res. 16:5835–5841. 2010.PubMed/NCBI View Article : Google Scholar
40	Bax C, Lotesoriere BJ, Sironi S and Capelli L: Review and comparison of cancer biomarker trends in urine as a basis for new diagnostic pathways. Cancers (Basel). 11(1244)2019.PubMed/NCBI View Article : Google Scholar
41	Cala M, Aldana J, Sánchez J, Guio J and Meesters RJW: Urinary metabolite and lipid alterations in Colombian Hispanic women with breast cancer: A pilot study. J Pharm Biomed Anal. 152:234–241. 2018.PubMed/NCBI View Article : Google Scholar
42	Pasikanti KK, Esuvaranathan K, Hong Y, Ho PC, Mahendran R, Raman Nee Mani L, Chiong E and Chan EC: Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. J Proteome Res. 12:3865–3873. 2013.PubMed/NCBI View Article : Google Scholar
43	Silva C, Perestrelo R, Silva P, Tomás H and Câmara JS: Breast cancer metabolomics: From analytical platforms to multivariate data analysis. A review. Metabolites. 9(102)2019.PubMed/NCBI View Article : Google Scholar
44	Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, et al: Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 71:7376–7386. 2011.PubMed/NCBI View Article : Google Scholar
45	Yu L, Jiang C, Huang S, Gong X, Wang S and Shen P: Analysis of urinary metabolites for breast cancer patients receiving chemotherapy by CE-MS coupled with on-line concentration. Clin Biochem. 46:1065–1073. 2013.PubMed/NCBI View Article : Google Scholar
46	Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, Nam SJ, Kim S, Bai SW and Chung BC: Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta. 400:63–69. 2009.PubMed/NCBI View Article : Google Scholar
47	Men Y, Li L, Zhang F, Kong X, Zhang W, Hao C and Wang G: Evaluation of heavy metals and metabolites in the urine of patients with breast cancer. Oncol Lett. 19:1331–1337. 2020.PubMed/NCBI View Article : Google Scholar
48	Asiago VM, Alvarado LZ, Shanaiah N, Gowda GAN, Owusu-Sarfo K, Ballas RA and Raftery D: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 70:8309–8318. 2010.PubMed/NCBI View Article : Google Scholar
49	Oakman C, Tenori L, Claudino WM, Cappadona S, Nepi S, Battaglia A, Bernini P, Zafarana E, Saccenti E, Fornier M, et al: Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann Oncol. 22:1295–1301. 2011.PubMed/NCBI View Article : Google Scholar
50	Tenori L, Oakman C, Claudino WM, Bernini P, Cappadona S, Nepi S, Biganzoli L, Arbushites MC, Luchinat C, Bertini I and Di Leo A: Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study. Mol Oncol. 6:437–444. 2012.PubMed/NCBI View Article : Google Scholar
51	Wei S, Liu L, Zhang J, Bowers J, Gowda GAN, Seeger H, Fehm T, Neubauer HJ, Vogel U, Clare SE and Raftery D: Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol. 7:297–307. 2013.PubMed/NCBI View Article : Google Scholar
52	Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B and Trédan O: A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 343:33–41. 2014.PubMed/NCBI View Article : Google Scholar
53	Tenori L, Oakman C, Morris PG, Gralka E, Turner N, Cappadona S, Fornier M, Hudis C, Norton L, Luchinat C and Di Leo A: Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol Oncol. 9:128–139. 2015.PubMed/NCBI View Article : Google Scholar
54	Kim Y, Koo I, Jung BH, Chung BC and Lee D: Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics. 11 (Suppl 2)(S4)2010.PubMed/NCBI View Article : Google Scholar
55	Bathen TF, Geurts B, Sitter B, Fjøsne HE, Lundgren S, Buydens LM, Gribbestad IS, Postma G and Giskeødegård GF: Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery. PLoS One. 8(e61578)2013.PubMed/NCBI View Article : Google Scholar
56	Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, Sørlie T, Børresen-Dale AL and Gribbestad IS: Merging transcriptomics and metabolomics-advances in breast cancer profiling. BMC Cancer. 10(628)2010.PubMed/NCBI View Article : Google Scholar
57	Debik J, Euceda LR, Lundgren S, Gythfeldt HDVL, Garred Ø, Borgen E, Engebraaten O, Bathen TF and Giskeødegård GF: Assessing treatment response and prognosis by serum and tissue metabolomics in breast cancer patients. J Proteome Res. 18:3649–3660. 2019.PubMed/NCBI View Article : Google Scholar
58	Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, et al: Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab. 4(12)2016.PubMed/NCBI View Article : Google Scholar
59	Chae EY, Shin HJ, Kim S, Baek HM, Yoon D, Kim S, Shim YE, Kim HH, Cha JH, Choi WJ, et al: The role of high-resolution magic angle spinning 1H nuclear magnetic resonance spectroscopy for predicting the invasive component in patients with ductal carcinoma in situ diagnosed on preoperative biopsy. PLoS One. 11(e0161038)2016.PubMed/NCBI View Article : Google Scholar
60	Euceda LR, Haukaas TH, Giskeødegård GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred Y, Garred G, et al: Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy. Metabolomics. 13(37)2017.
61	Cala MP, Aldana J, Medina J, Sánchez J, Guio J, Wist J and Meesters RJW: Multiplatform plasma metabolic and lipid fingerprinting of breast cancer: A pilot control-case study in Colombian Hispanic women. PLoS One. 13(e0190958)2018.PubMed/NCBI View Article : Google Scholar
62	Lécuyer L, Victor Bala A, Deschasaux M, Bouchemal N, Nawfal Triba M, Vasson MP, Rossary A, Demidem A, Galan P, Hercberg S, et al: NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer. Int J Epidemiol. 47:484–494. 2018.PubMed/NCBI View Article : Google Scholar
63	Suman S, Sharma RK, Kumar V, Sinha N and Shukla Y: Metabolic fingerprinting in breast cancer stages through ¹H NMR spectroscopy-based metabolomic analysis of plasma. J Pharm Biomed Anal. 160:38–45. 2018.PubMed/NCBI View Article : Google Scholar
64	Louis E, Bervoets L, Reekmans G, De Jonge E, Mesotten L, Thomeer M and Adriaensens P: Phenotyping human blood plasma by ¹H-NMR: A robust protocol based on metabolite spiking and its evaluation in breast cancer. Metabolomics. 11:225–236. 2015.
65	Vignoli A, Muraro E, Miolo G, Tenori L, Turano P, Di Gregorio E, Steffan A, Luchinat C and Corona G: Effect of estrogen receptor status on circulatory immune and metabolomics profiles of HER2-positive breast cancer patients enrolled for neoadjuvant targeted chemotherapy. Cancers (Basel). 12(314)2020.PubMed/NCBI View Article : Google Scholar
66	McCartney A, Vignoli A, Tenori L, Fornier M, Rossi L, Risi E, Luchinat C, Biganzoli L and Di Leo A: Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. NPJ Breast Cancer. 5(26)2019.PubMed/NCBI View Article : Google Scholar
67	Jiang L, Lee SC and Ng TC: Pharmacometabonomics analysis reveals serum formate and acetate potentially associated with varying response to gemcitabine-carboplatin chemotherapy in metastatic breast cancer patients. J Proteome Res. 17:1248–1257. 2018.PubMed/NCBI View Article : Google Scholar
68	Wojtowicz W, Wróbel A, Pyziak K, Tarkowski R, Balcerzak A, Bębenek M and Młynarz P: Evaluation of MDA-MB-468 cell culture media analysis in predicting triple-negative breast cancer patient sera metabolic profiles. Metabolites. 10(173)2020.PubMed/NCBI View Article : Google Scholar
69	Men Y, Li L, Zhang F, Kong X, Zhang W, Hao C, et al: Evaluation of heavy metals and metabolites in the urine of patients with breast cancer. Oncol Lett. 19:1331–1337. 2020.PubMed/NCBI View Article : Google Scholar
70	Li N, Deng Y, Zhou L, Tian T, Yang S, Wu Y, Zheng Y, Zhai Z, Hao Q, Song D, et al: Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: Results from the Global Burden of Disease Study 2017. J Hematol Oncol. 12(140)2019.PubMed/NCBI View Article : Google Scholar
71	Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, Capstick V, Faught W and Sawyer MB: Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res. 16:5835–5841. 2010.PubMed/NCBI View Article : Google Scholar
72	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011.PubMed/NCBI View Article : Google Scholar
73	Lau AN and Vander Heiden MG: Metabolism in the tumor microenvironment. Annu Rev Cancer Biol. 4:17–40. 2020.
74	Phan LM, Yeung SCJ and Lee MH: Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 11:1–19. 2014.PubMed/NCBI View Article : Google Scholar
75	Sullivan LB, Gui DY and Van Der Heiden MG: Altered metabolite levels in cancer: Implications for tumour biology and cancer therapy. Nat Rev Cancer. 16:680–693. 2016.PubMed/NCBI View Article : Google Scholar
76	Gu I, Gregory E, Atwood C, Lee SO and Song YH: Exploring the role of metabolites in cancer and the associated nerve crosstalk. Nutrients. 14(1722)2022.PubMed/NCBI View Article : Google Scholar
77	Potter M, Newport E and Morten KJ: The Warburg effect: 80 Years on. Biochem Soc Trans. 44:1499–1505. 2016.PubMed/NCBI View Article : Google Scholar
78	Nalbantoglu S and Karadag A: Metabolomics bridging proteomics along metabolites/oncometabolites and protein modifications: Paving the way toward integrative multiomics. J Pharm Biomed Anal. 199(114031)2021.PubMed/NCBI View Article : Google Scholar
79	Kinnaird A, Zhao S, Wellen KE and Michelakis ED: Metabolic control of epigenetics in cancer. Nat Rev Cancer. 16:694–707. 2016.PubMed/NCBI View Article : Google Scholar
80	Al-Shajrawi OM, Basit E and Baig AA: HIF1 (rs11549465) and NFKB1 (rs28362491) variants association with obesity in Malaysia. Meta Gene. 25(100753)2020.
81	Choi YK and Park KG: Targeting glutamine metabolism for cancer treatment. Biomol Ther (Seoul). 26:19–28. 2018.PubMed/NCBI View Article : Google Scholar
82	Butler M, van der Meer LT and van Leeuwen FN: Amino acid depletion therapies: Starving cancer cells to death. Trends Endocrinol Metab. 32:367–381. 2021.PubMed/NCBI View Article : Google Scholar
83	Wang ZH, Peng WB, Zhang P, Yang XP and Zhou Q: Lactate in the tumour microenvironment: From immune modulation to therapy. EBioMedicine. 73(103627)2021.PubMed/NCBI View Article : Google Scholar
84	Doldo E, Costanza G, Agostinelli S, Tarquini C, Ferlosio A, Arcuri G, Passeri D, Scioli MG and Orlandi A: Vitamin A, cancer treatment and prevention: The new role of cellular retinol binding proteins. Biomed Res Int. 2015(624627)2015.PubMed/NCBI View Article : Google Scholar
85	Zeng LH, Wang QM, Feng LY, Ke YD, Xu QZ, Wei AY, Zhang C and Ying RB: High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition. Onco Targets Ther. 12:7405–7413. 2019.PubMed/NCBI View Article : Google Scholar
86	Sailo BL, Banik K, Padmavathi G, Javadi M, Bordoloi D and Kunnumakkara AB: Tocotrienols: The promising analogues of vitamin E for cancer therapeutics. Pharmacol Res. 130:259–272. 2018.PubMed/NCBI View Article : Google Scholar
87	Miyazawa S, Moriya S, Kokuba H, Hino H, Takano N and Miyazawa K: Vitamin K₂ induces non-apoptotic cell death along with autophagosome formation in breast cancer cell lines. Breast Cancer. 27:225–235. 2020.PubMed/NCBI View Article : Google Scholar
88	Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu J, Gaur S, Forman HJ, Zhang H, Zheng S, et al: Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal. 7(ra31)2014.PubMed/NCBI View Article : Google Scholar
89	Cheng CT, Qi Y, Wang YC, Chi KK, Chung Y, Ouyang C, Chen YR, Oh ME, Sheng X, Tang Y, et al: Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction. Commun Biol. 1(178)2018.PubMed/NCBI View Article : Google Scholar
90	Ji JX, Cochrane DR, Tessier-Cloutier B, Chen SY, Ho G, Pathak KV, Alcazar IN, Farnell D, Leung S, Cheng A, et al: Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase-deficient ovarian cancer, including small-cell carcinoma of the ovary, hypercalcemic type. Clin Cancer Res. 26:4402–4413. 2020.PubMed/NCBI View Article : Google Scholar
91	Krall AS, Xu S, Graeber TG, Braas D and Christofk HR: Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun. 7(11457)2016.PubMed/NCBI View Article : Google Scholar
92	Hoang G, Udupa S and Le A: Application of metabolomics technologies toward cancer prognosis and therapy. Int Rev Cell Mol Biol. 347:191–223. 2019.PubMed/NCBI View Article : Google Scholar
93	Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, et al: Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci USA. 113:E5328–E5336. 2016.PubMed/NCBI View Article : Google Scholar
94	Lane AN, Fan TWM and Higashi RM: Isotopomer-based metabolomic analysis by NMR and mass spectrometry. Methods Cell Biol. 84:541–588. 2008.PubMed/NCBI View Article : Google Scholar
95	Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, et al: Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 15:110–121. 2012.PubMed/NCBI View Article : Google Scholar
96	Beger R: A review of applications of metabolomics in cancer. Metabolites. 3:552–574. 2013.PubMed/NCBI View Article : Google Scholar
97	Zhang A, Sun H, Wang P, Han Y and Wang X: Modern analytical techniques in metabolomics analysis. Analyst. 137:293–300. 2012.PubMed/NCBI View Article : Google Scholar
98	Lyon DE, Starkweather A, Yao Y, Garrett T, Kelly DL, Menzies V, Dereziński P, Datta S, Kumar S and Jackson-Cook C: Pilot study of metabolomics and psychoneurological symptoms in women with early stage breast cancer. Biol Res Nurs. 20:227–236. 2018.PubMed/NCBI View Article : Google Scholar
99	Silva CL, Perestrelo R, Silva P, Tomás H and Câmara JS: Volatile metabolomic signature of human breast cancer cell lines. Sci Rep. 7(43969)2017.PubMed/NCBI View Article : Google Scholar
100	Cífková E, Lísa M, Hrstka R, Vrána D, Gatěk J, Melichar B and Holčapek M: Correlation of lipidomic composition of cell lines and tissues of breast cancer patients using hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry and multivariate data analysis. Rapid Commun Mass Spectrom. 31:253–263. 2017.PubMed/NCBI View Article : Google Scholar
101	Cavaco C, Pereira JAM, Taunk K, Taware R, Rapole S, Nagarajaram H and Câmara JS: Screening of salivary volatiles for putative breast cancer discrimination: An exploratory study involving geographically distant populations. Anal Bioanal Chem. 410:445–468. 2018.PubMed/NCBI View Article : Google Scholar
102	Porto-Figueira P, Pereira JAM and Câmara JS: Exploring the potential of needle trap microextraction combined with chromatographic and statistical data to discriminate different types of cancer based on urinary volatomic biosignature. Anal Chim Acta. 1023:53–63. 2018.PubMed/NCBI View Article : Google Scholar
103	Budczies J, Brockmöller SF, Müller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, Griffin JL, Orešič M, Dietel M, Denkert C and Fiehn O: Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: Alterations in glutamine and beta-alanine metabolism. J Proteomics. 94:279–288. 2013.PubMed/NCBI View Article : Google Scholar
104	Dougan MM, Li Y, Chu LW, Haile RW, Whittemore AS, Han SS, Moore SC, Sampson JN, Andrulis IL, John EM and Hsing AW: Metabolomic profiles in breast cancer: A pilot case-control study in the breast cancer family registry. BMC Cancer. 18(532)2018.PubMed/NCBI View Article : Google Scholar
105	Sas KM, Karnovsky A, Michailidis G and Pennathur S: Metabolomics and diabetes: Analytical and computational approaches. Diabetes. 64:718–732. 2015.PubMed/NCBI View Article : Google Scholar
106	Ahad T and Nissar J: Fingerprinting in determining the adultration of food. J Pharmacogn Phytochem. 6:1543–1553. 2017.
107	Claudino WM, Goncalves PH, di Leo A, Philip PA and Sarkar FH: Metabolomics in cancer: A bench-to-bedside intersection. Crit Rev Oncol Hematol. 84:1–7. 2012.PubMed/NCBI View Article : Google Scholar
108	De Castro F, Benedetti M, Del Coco L and Fanizzi FP: NMR-based metabolomics in metal-based drug research. Molecules. 24(2240)2019.PubMed/NCBI View Article : Google Scholar
109	Cacciola F, Farnetti S, Dugo P, Marriott PJ and Mondello L: Comprehensive two-dimensional liquid chromatography for polyphenol analysis in foodstuffs. J Sep Sci. 40:7–24. 2017.PubMed/NCBI View Article : Google Scholar
110	Emwas AHM: The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. Methods Mol Biol. 1277:161–193. 2015.PubMed/NCBI View Article : Google Scholar
111	Beltran A, Suarez M, Rodríguez MA, Vinaixa M, Samino S, Arola L, Correig X and Yanes O: Assessment of compatibility between extraction methods for NMR- and LC/MS-based metabolomics. Anal Chem. 84:5838–5844. 2012.PubMed/NCBI View Article : Google Scholar
112	Emwas AH, Roy R, McKay RT, Tenori L, Saccenti E, Gowda GAN, Raftery D, Alahmari F, Jaremko L, Jaremko M and Wishart DS: Nmr spectroscopy for metabolomics research. Metabolites. 9(123)2019.PubMed/NCBI View Article : Google Scholar
113	Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R and Griffin JL: Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 40:387–426. 2011.PubMed/NCBI View Article : Google Scholar
114	Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S and Zhang A: Small molecule metabolites: Discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther. 8(132)2023.PubMed/NCBI View Article : Google Scholar
115	Burke HB: Predicting clinical outcomes using molecular biomarkers. Biomark Cancer. 8:89–99. 2016.PubMed/NCBI View Article : Google Scholar
116	Carlomagno N, Incollingo P, Tammaro V, Peluso G, Rupealta N, Chiacchio G, Sandoval Sotelo ML, Minieri G, Pisani A, Riccio E, et al: Diagnostic, predictive, prognostic, and therapeutic molecular biomarkers in third millennium: A breakthrough in gastric cancer. Biomed Res Int. 2017(7869802)2017.PubMed/NCBI View Article : Google Scholar
117	Mayeux R: Biomarkers: Potential uses and limitations. NeuroRx. 1:182–188. 2004.PubMed/NCBI View Article : Google Scholar
118	Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E and Cardoso F: Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 75:284–298. 2017.PubMed/NCBI View Article : Google Scholar
119	Brennan M and Lim B: The actual role of receptors as cancer markers, biochemical and clinical aspects: Receptors in breast cancer. Adv Exp Med Biol. 867:327–337. 2015.PubMed/NCBI View Article : Google Scholar
120	Li Z, Wei H, Li S, Wu P and Mao X: The role of progesterone receptors in breast cancer. Drug Des Devel Ther. 16:305–314. 2022.PubMed/NCBI View Article : Google Scholar
121	Brisken C, Hess K and Jeitziner R: Progesterone and overlooked endocrine pathways in breast cancer pathogenesis. Endocrinology. 156:3442–3450. 2015.PubMed/NCBI View Article : Google Scholar
122	Trabert B, Sherman ME, Kannan N and Stanczyk FZ: Progesterone and breast cancer. Endocr Rev. 41:320–344. 2020.PubMed/NCBI View Article : Google Scholar